Physician profile
Charles E Rassier
NPI 1902025794
$3,876.34
in general payments reported to CMS, 2019-2025
23 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $463 · 2021: $678 · 2022: $339 · 2023: $863 · 2024: $349 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $623.19 | 2020-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Allergan, INC. | $595.74 | 2019-2022 | |
| Abbvie INC. | $576.75 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $531.37 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $182.41 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $177.39 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $148.05 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $132.62 | 2019 | |
| Dompe US, INC. | $107.95 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $94.18 | 2025 | |
| Thea Pharma INC. | $86.40 | 2023-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $84.17 | 2019-2022 | |
| Alcon Vision LLC | $81.53 | 2022-2024 | Rocklatan, Clareon |
| New World Medical,INC. | $80.58 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Johnson & Johnson Vision Care, INC. | $78.77 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $59.87 | 2021-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $53.39 | 2020-2021 | |
| Ocular Therapeutix, INC. | $43.03 | 2022-2025 | Dextenza |
| Sight Sciences, INC. | $36.64 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Eyevance Pharmaceuticals LLC | $29.29 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $27.45 | 2022 | |
| Mallinckrodt Hospital Products INC. | $26.86 | 2020 | |
| Apellis Pharmaceuticals, INC. | $18.71 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rassier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.